Clinical Trial Update: Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and immunogenicity of V114 compared with Prevnar 13 in adults ≥65 previously vaccinated with PPSV23; results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)
• V114 (15-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infections | Phase 2 | Status: COMPLETED | Results posted: 2019-08-14